ERBB2 and adenocarcinoma: On the contrary, Pugh et al. showed that HER2-neu positivity on fluorescence in situ hybridization was not associated with EGFR mutations or amplifications, gender, ethnicity, smoking status, adenocarcinoma histology and gefitinib activity [19].